Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation

• Published in: International journal of molecular sciences Vol. 24; no. 10; p. 8547
• Main Authors: Ma, Xiao, Iyer, Seethalakshmi R, Ma, Xiaoyu, Reginauld, Shawn H, Chen, Yang, Pan, Shuchong, Zheng, Ye, Moroni, Dante G, Yu, Yue, Zhang, Lianwen, Cannone, Valentina, Chen, Horng H, Ferrario, Carlos M, Sangaralingham, S Jeson, Burnett, Jr, John C
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 10.05.2023; MDPI
• Subjects: Aldosterone; Analysis; ANGII type 1 receptor (AT1); Angiotensin; Angiotensin II; angiotensin II (ANGII); Angiotensin II - pharmacology; Animals; Atrial Natriuretic Factor - metabolism; Atrial Natriuretic Factor - pharmacology; Correlation analysis; Cyclic GMP; Cyclic GMP - metabolism; cyclic guanosine monophosphate (cGMP); Cyclic guanylic acid; Disease; Guanylate cyclase; Guanylate Cyclase - metabolism; Humans; Hypertension; In vivo methods and tests; Investigations; natriuretic peptide system (NPS); Natriuretic Peptide, Brain; Natriuretic Peptides; Nitric oxide; particulate guanylyl cyclase A (GC-A); Peptides; Plasma; Protein kinase C; Rats; Receptors, Atrial Natriuretic Factor - metabolism; Regression analysis; Renin; renin angiotensin aldosterone system (RAAS); Surface plasmon resonance; Urine; Massachusetts; California; angiotensin II (ANGII); natriuretic peptide system (NPS); protein kinase C (PKC); particulate guanylyl cyclase A (GC-A); ANGII type 1 receptor (AT1); cyclic guanosine monophosphate (cGMP); renin angiotensin aldosterone system (RAAS)
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24108547

The natriuretic peptide system (NPS) and renin-angiotensin-aldosterone system (RAAS) function oppositely at multiple levels. While it has long been suspected that angiotensin II (ANGII) may directly suppress NPS activity, no clear evidence to date supports this notion. This study was designed to systematically investigate ANGII-NPS interaction in humans, in vivo, and in vitro. Circulating atrial, b-type, and c-type natriuretic peptides (ANP, BNP, CNP), cyclic guanosine monophosphate (cGMP), and ANGII were simultaneously investigated in 128 human subjects. Prompted hypothesis was validated in vivo to determine the influence of ANGII on ANP actions. The underlying mechanisms were further explored via in vitro approaches. In humans, ANGII demonstrated an inverse relationship with ANP, BNP, and cGMP. In regression models predicting cGMP, adding ANGII levels and the interaction term between ANGII and natriuretic peptides increased the predictive accuracy of the base models constructed with either ANP or BNP, but not CNP. Importantly, stratified correlation analysis further revealed a positive association between cGMP and ANP or BNP only in subjects with low, but not high, ANGII levels. In rats, co-infusion of ANGII even at a physiological dose attenuated cGMP generation mediated by ANP infusion. In vitro, we found the suppressive effect of ANGII on ANP-stimulated cGMP requires the presence of ANGII type-1 (AT ) receptor and mechanistically involves protein kinase C (PKC), as this suppression can be substantially rescued by either valsartan (AT blocker) or Go6983 (PKC inhibitor). Using surface plasmon resonance (SPR), we showed ANGII has low binding affinity to the guanylyl cyclase A (GC-A) receptor compared to ANP or BNP. Our study reveals ANGII is a natural suppressor for the cGMP-generating action of GC-A via AT /PKC dependent manner and highlights the importance of dual-targeting RAAS and NPS in maximizing beneficial properties of natriuretic peptides in cardiovascular protection.